Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3580 | Serial seroconversion measurements in hospital employees during the COVID-19 pandemic Wiki | 1.00 |
| drug765 | COVID-19 convalescent plasma (CCP) plus standard of care (SOC) Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
A prospective, randomized, placebo-controlled, double-blinded, phase III clinical trial of the therapeutic use of convalescent plasma in the treatment of patients with moderate to severe COVID-19
Description: Proportion of participants with successful treatment outcome, defined as clinical improvement (≥ 2 points on WHO R&D BOSCI 1) by Day 28 post-randomisation.
Measure: Clinical Improvement Time: Day 28Description: 1. Proportion of participants with adverse events of special interest (Transfusion-Associated Circulatory Overload (TACO); Transfusion-Related Acute Lung Injury (TRALI); allergic transfusion reaction).
Measure: Adverse Events of special interest Time: Day 28Description: 2. Proportion of participants with serious adverse events.
Measure: Serious Adverse Events Time: Day 28Description: 3. Proportion of participants surviving at Day 28 post-randomisation.
Measure: Survival Time: Day 28Description: 4. Proportion of participants requiring invasive mechanical ventilation.
Measure: Invasive mechanical ventilation Time: Day 28Description: 5. Proportion of participants with moderate and severe ARDS.
Measure: Disease severity Time: Day 28Description: 6. Time from randomization to death, clinical improvement, ICU admission, and invasive mechanical ventilation.
Measure: Time to outcomes of interest Time: Day28Description: 7. Duration of hospitalisation, ICU stay, and mechanical ventilation in survivors.
Measure: Length of stay meausures Time: Day28Description: 8. Proportion negative SARS-CoV-2 PCR at Day 28; time to viral clearance (PCR-negativity); change in SARS-CoV-2 PCR Ct value.
Measure: SARS-CoV PCR Time: Day28Description: 9. Proportion with and time to normalisation of inflammatory markers, including CRP, lymphocyte count, D-dimer, ferritin.
Measure: Inflammatory markers Time: Day28Description: 10. Worsening of radiographic abnormalities.
Measure: Radiography Time: Day28Description: 11. Proportion with and time to resolution of fever and hypoxia.
Measure: Fever & Hypoxia Time: Day28Description: 12. Proportion of patients with HIV infection and other comorbidities (obesity, diabetes, hypertension) with primary efficacy outcome.
Measure: patients with HIV infection and other comorbidities Time: Day 28Description: 13. Relationship between timing of transfusion from symptom onset and primary efficacy outcome.
Measure: Timing of IP & Efficacy Outcome Time: Day 28Description: 14. Relationship between convalescent plasma neutralizing antibody titers and primary efficacy outcome
Measure: Neutralising Ab Time: Day28Description: 15. Comparison of anti-SARS-CoV-2 titer dynamics between treatment arms
Measure: SARS CoV Antibody titre Time: Day28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports